Rapport Therapeutics, Inc. Common Stock (RAPP) - Stock Analysis
Last updated: Jul 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Mid-July peak ⢠Lower highs ⢠Support holding Support Level: $40.0â$40.2 Resistance Level: $41.7â$42.6 Over the last month, RAPP drifted higher but has pulled back from its mid-July high, leaving $41.7â$42.6 as near-term resistance and $40.0â$40.2 as key support to watch before the trend strengthens again.
Sentiment & News
Key News Insights: ⢠Moderate Buy ⢠$57.86 Target ⢠COO Sale Rapport Therapeutics shows broadly supportive analyst sentiment with a $57.86 average target and Moderate Buy rating, but a notable COO share sale slightly tempers the outlook.
AI Summary
RAPP now looks like a well-funded catalyst platform rather than a fragile one-shot biotech, with cash through H2 2029 and multiple shots on goal, but after the recent run the stock likely needs RAP-219 Phase 3/bipolar mania data to deliver registrational-quality proof or the valuation upside could stall.
Description
Rapport Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for central nervous system disorders. Its lead candidate, RAP-219, is a high-affinity inhibitor of TARPy8-containing AMPA receptors being evaluated for focal epilepsy and other CNS indications; the pipeline also includes an additional TARPy8 program and nicotinic acetylcholine receptor projects targeting chronic pain and hearing disorders. The company was incorporated in 2022, renamed from Precision Neuroscience NewCo in October 2022, and is based in Boston, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 15 | Sep 22 | RAPP | Rapport Therapeutics, Inc. Common Stock | Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term. | Closed | +5.6% |